Emily Martin, MD
Endocrinology, Diabetes & Metabolism · Butler, PANPI 1235344250
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $198,627 of the $227,487 with a category attached, or 87.3%. Novo Nordisk accounts for 96.2% of it on its own, with 41 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 683 payments — averaging $333.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$219K
- Cequr Corporation$2K
- Lilly USA, LLC$1K
- AstraZeneca$751
- Sanofi-aventis U.S. LLC$398
- Medtronic$394
- plus $4K from 36 others
What the payments were for
- Consulting fees$2,3041%
- Speaking & faculty fees$198,62787%
- Travel & lodging$11,6895%
- Food & beverage$14,6476%
- Education$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 317 | $218,871 |
| Cequr Corporation | 4 | $1,825 |
| Lilly USA, LLC | 91 | $1,352 |
| AstraZeneca(2 entities) | 26 | $751 |
| Sanofi-aventis U.S. LLC | 26 | $398 |
| Medtronic(2 entities) | 9 | $394 |
| Amgen | 16 | $365 |
| Boehringer Ingelheim | 21 | $361 |
| BD | 11 | $276 |
| BETA Bionics, Inc. | 10 | $255 |
| Tandem Diabetes Care, Inc. | 11 | $225 |
| Bayer | 11 | $191 |
| Dexcom, Inc. | 9 | $191 |
| Johnson & Johnson | 13 | $188 |
| AbbVie | 10 | $184 |
| IBSA Pharma Inc. | 8 | $157 |
| Insulet Corporation | 9 | $144 |
| Abbott | 9 | $144 |
| Amneal Pharmaceuticals LLC | 7 | $131 |
| Xeris Pharmaceuticals, Inc. | 6 | $107 |
| Amarin Pharma, Inc. | 7 | $105 |
| Amphastar Pharmaceuticals, Inc. | 5 | $84 |
| Embecta Corp. | 3 | $75 |
| Ascendis Pharma Endocrinology Inc | 4 | $70 |
| Merck | 5 | $69 |
| Shire North American Group Inc | 4 | $63 |
| Antares Pharma, Inc. | 4 | $63 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Corcept Therapeutics | 4 | $54 |
| Radius Health, Inc. | 3 | $54 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Smith+Nephew | 2 | $40 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Valeritas, Inc. | 1 | $20 |
| Soleno Therapeutics, Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $18 |
| Alvogen Inc | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Kvk-tech, Inc. | 3 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$94,843
- RYBELSUS$86,994
- Tresiba$10,349
- Xultophy 100/3.6$6,630
- Victoza$2,295
- CeQur Simplicity$1,751
- iLet Bionic Pancreas$361
- INPEN SMART INSULIN DELIVERY SYSTEM$156
- Wegovy$124
- FARXIGA$124
- iLet Insulin Infusion Kit Inset$120
- iLet Insulin Infusion Kit Contact Detach$120
- EVENITY$115
- MINIMED 780G$112
How this compares
$227,487 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 467 | $656,104 |
| TrulicityDulaglutide | 460 | $630,141 |
| JardianceEmpagliflozin | 542 | $593,065 |
| MounjaroTirzepatide | 232 | $288,205 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $89,088 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $66,059 |
| FarxigaDapagliflozin Propanediol | 50 | $58,819 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $53,637 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $41,517 |
| Humalog Kwikpen U-100Insulin Lispro | 129 | $39,716 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 65 | $38,662 |
| ProliaDenosumab | 22 | $36,217 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 249 | $35,145 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 64 | $34,030 |
| InvokanaCanagliflozin | 19 | $29,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $1,352 | $929,775743 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $218,871 | $694,259528 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $361 | $630,968580 claims |
| AstraZenecaFarxiga | $751 | $58,81950 claims |
| AmgenProlia | $365 | $36,21722 claims |
| Johnson & JohnsonInvokana | $188 | $29,55519 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $398 | $21,48239 claims |
| AbbVieSynthroid | $184 | $13,080146 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $131 | $7,099467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Butler
- Sanjay DixitButler$42K
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.